Copyright
©The Author(s) 2025.
World J Diabetes. Jul 15, 2025; 16(7): 108344
Published online Jul 15, 2025. doi: 10.4239/wjd.v16.i7.108344
Published online Jul 15, 2025. doi: 10.4239/wjd.v16.i7.108344
Table 1 Baseline characteristics of subjects according to the incident end-stage renal disease
Variable | None ESRD (n = 2471672) | ESRD (n = 23359) | P value | Variable | None ESRD (n = 2471672) | ESRD (n = 23359) | P value |
Age | 59.56 ± 12 | 63.43 ± 11.4 | 0.0001 | DM duration | 0.0001 | ||
Age group | 0.0001 | New onset | 720322 (29.14) | 1909 (8.17) | |||
< 40 | 120544 (4.88) | 542 (2.32) | < 5 years | 674433 (27.29) | 2604 (11.15) | ||
40-64 | 1502637 (60.79) | 11435 (48.95) | 5-9 years | 485967 (19.66) | 3978 (17.03) | ||
≥ 65 | 848491 (34.33) | 11382 (48.73) | ≥ 10 years | 590950 (23.91) | 14868 (63.65) | ||
Sex male (%) | 1486398 (60.14%) | 15637 (66.94%) | 0.0001 | BMI (kg/m2) | 25.34 ± 3.54 | 25 ± 3.67 | 0.0001 |
Low income1 | 530489 (21.46) | 5878 (25.16) | 0.0001 | BMI_5 level | 0.0001 | ||
Smoking | 0.0001 | < 18.5 | 33269 (1.35) | 477 (2.04) | |||
Never | 1360211 (55.03) | 12376 (52.98) | 18.5-23 | 575343 (23.28) | 6379 (27.31) | ||
Ex- | 553739 (22.4) | 5820 (24.92) | 23-25 | 597529 (24.18) | 5557 (23.79) | ||
Current | 557722 (22.56) | 5163 (22.1) | 25-30 | 1032471 (41.77) | 8857 (37.92) | ||
Drinking | 0.0001 | ≥ 30 | 233060 (9.43) | 2089 (8.94) | |||
None | 1423230 (57.58) | 16532 (70.77) | WC cm | 86.15 ± 8.98 | 87.08 ± 9.54 | 0.0001 | |
Moderate | 822332 (33.27) | 5590 (23.93) | WC level (M/F) | 0.0001 | |||
Heavy2 | 226110 (9.15) | 1237 (5.3) | < 80/75 | 361141 (14.61) | 3633 (15.55) | ||
Regular exercise | 537065 (21.73) | 4437 (18.99) | 0.0001 | < 85/80 | 489684 (19.81) | 4167 (17.84) | |
Hypertension | 1424600 (57.64) | 20241 (86.65) | 0.0001 | < 90/85 | 604127 (24.44) | 5045 (21.6) | |
Dyslipidemia | 1411286 (57.1) | 16770 (71.79) | 0.0001 | < 95/90 | 485423 (19.64) | 4660 (19.95) | |
CKD3 | 223756 (9.05) | 16054 (68.73) | 0.0001 | < 100/95 | 291335 (11.79) | 2911 (12.46) | |
Proteinuria | 156756 (6.34) | 13927 (59.62) | 0.0001 | ≥ 100/95 | 239962 (9.71) | 2943 (12.6) | |
SBP (mmHg) | 128.4 ± 14.99 | 134.66 ± 18.01 | 0.0001 | FBS mg/dL | 144.46 ± 45.34 | 156.02 ± 74.42 | 0.0001 |
DBP (mmHg) | 78.08 ± 9.94 | 78.17 ± 11.13 | 0.0001 | TC mg/dL | 185.3 ± 43.63 | 181.57 ± 51.26 | 0.0001 |
DM medication | 1751350 (70.86) | 21450 (91.83) | 0.0001 | HDL-C mg/dL | 51 ± 14.71 | 46.97 ± 14.97 | 0.0001 |
OHA ≥ 3 | 578752 (23.42) | 8376 (35.86) | 0.0001 | LDL-C mg/dL | 103.17 ± 38.36 | 99.19 ± 42.32 | 0.0001 |
Metformin | 1598169 (64.66) | 14570 (62.37) | 0.0001 | eGFR | 89.81 ± 52.98 | 52.22 ± 40.69 | 0.0001 |
SGLT-2 inhibitor | 65835 (2.66) | 567 (2.43) | 0.0256 | TG (mg/dL)4 | 137.57 (137.47-137.66) | 155.88 (154.77-157.01) | 0.0001 |
- Citation: Bae EH, Lim SY, Kim BS, Han KD, Suh SH, Choi HS, Kim CS, Ma SK, Kim SW. Exercise intensity and the risk of end-stage renal disease in diabetes: A nationwide population-based study. World J Diabetes 2025; 16(7): 108344
- URL: https://www.wjgnet.com/1948-9358/full/v16/i7/108344.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i7.108344